Compare BGSF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | ENTX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 62.6M |
| IPO Year | 2013 | 2015 |
| Metric | BGSF | ENTX |
|---|---|---|
| Price | $5.70 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 20.3K | ★ 173.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 34.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $93,310,000.00 | $42,000.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.91 | $0.91 |
| 52 Week High | $8.20 | $3.22 |
| Indicator | BGSF | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 48.33 |
| Support Level | $5.92 | $1.17 |
| Resistance Level | $6.38 | $1.61 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 42.86 | 56.25 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.